MAP3K6/ASK2

MAP3K6, also known as MEKK6, functions as a mitogen-activated protein kinase kinase kinase (MAP3K) regulating angiogenesis and tumorigenesis through modulation of vascular endothelial growth factor (VEGF) expression^[1]. Under both normoxic and hypoxic conditions, MAP3K6 influences endothelial proliferation and capillary network formation, highlighting its role in vascular remodeling^[1]. Germline variants of MAP3K6 have been linked to familial gastric cancer, acting as a tumor suppressor and predisposing factor in hereditary cases lacking CDH1 mutations^[2]. Additionally, MAP3K6 mutations are associated with neurovascular disorders characterized by stroke, cognitive impairment, and tremor, potentially via altered VEGF-mediated angiogenic pathways^[3]. ASK2, a serine/threonine kinase closely related to ASK1, operates as a functional MAP3K only within a heteromeric complex with ASK1, stabilizing ASK2 and enhancing oxidative stress-induced JNK activation^[4]. In this complex, ASK2 reciprocally phosphorylates and activates ASK1, demonstrating a cooperative mechanism distinct from ASK1 alone^[4]. In inflammatory and infectious contexts, the ASK1/ASK2 complex regulates NLRP3 inflammasome priming, with ASK2 playing a dominant role in mediating lethal pathology in vivo^[5][6]. Compared with related isoforms such as ASK1, ASK2 is more directly implicated in proapoptotic responses while ASK1 predominantly drives cytokine-mediated inflammatory signaling^[7][4]. For experimental applications, targeting ASK2 within the heteromeric ASK1/ASK2 complex may allow selective modulation of stress-induced apoptosis without broadly affecting ASK1-dependent inflammatory pathways^[4][5].

References: